Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs||CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs are patient hematopoietic progenitor cells that have been transduced using a lentiviral vector containing HIV genes for a short hairpin RNA that interferes with CCR5 expression, TRIM5a, and a TAT activation response (TAR) decoy as well as a mutated version of human CD25, which may result in resistance to HIV infection and HIV-related tumors (NCI Drug Dictionary).|
|Carmustine||Becenun||BCNU||Chemotherapy - Alkylating 14||Becenun (carmustine) is an antineoplastic alkylating agent, which cross-links DNA and disrupts the cell-cycle (NCI Drug Dictionary).|
|Cytarabine||Cytosar-U||Ara-C||Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 4||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Melphalan||Alkeran||Chemotherapy - Alkylating 14||Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02797470||Phase Ib/II||Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan||Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant||Recruiting|